My price estimates have been similar to yours JP. A couple of factors may influence a higher price. All inclusive Lympro partner for CLIA and FDA commercialization. Higher than expected guidance. Bigger upfront payment. Ex-US strategy? Also, what about Lympro TBI. I think it's imminent for data just due to the title of this Summit and comments by GC and Dr Lowe. My point is there are a lot of factors. I personally think we are going to be surprised to the upside. I really do think they are trying to knock it out of the park with Diagnostics division to support further build out of MANF and Eltoprazine. If guidance is what Watson mentioned today, partner happens, and maybe TBI folds in - Lympro itself could cause AMBS to uplist. Think about it -$250M revenue in 2015 and $500-$600M in 2016. That would certainly do it.